Healthcare costs in patients with metastatic lung cancer receiving chemotherapy

BMC Health Services Research

Volumn 11, Issue , 2011, Pages

  Vera Llonch, Montserrat ^a   Weycker, Derek ^a   Glass, Andrew ^b   Gao, Sue ^c   Borker, Rohit ^c   Barber, Beth ^c   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b KAISER PERMANENTE   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ARTICLE; COST OF ILLNESS; ECONOMICS; FOLLOW UP; HEALTH CARE COST; HEALTH SERVICES RESEARCH; HOSPITALIZATION; HUMAN; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ANTINEOPLASTIC AGENTS; COST OF ILLNESS; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HOSPITALIZATION; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; OFFICE VISITS; UNITED STATES; YOUNG ADULT;

EID: 81055127613     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-11-305     Document Type: Article

References (14)

1. American Cancer Society, Cancer Facts & Figures 2009 Atlanta: American Cancer Society 2009 22054936
2. SEER Cancer Statistics Review, 1975-2003. Ries LAG, Harkins D, Krapcho M, et al. Bethesda, MD, National Cancer Institute 2006
3. National Cancer Institute, US National Institutes of Health http://www.cancer.gov (last accessed June 15 2010)
4. Cost of care for elderly cancer patients in the United States. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown ML, J Natl Cancer Inst 2008 100 630 41 10.1093/jnci/djn103 18445825
5. clinical practice guidelines in oncology (NCCN v1. 2010). National Comprehensive Cancer Network (NCCN), http://www.nccn.org (last accessed June 16, 2010)
6. Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. Karnon J, Kerr GR, Jack W, Papo NL, Cameron DA, Br J Cancer 2007 97 479 85 10.1038/sj.bjc.6603887 17653077 (Pubitemid 47258450)
7. Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States. Lang K, Marciniak MD, Faries D, Stokes M, Buesching D, Earle C, Treat J, Babineaux S, Morissette N, Thompson D, Value Health 2009 12 4 481 8 10.1111/j.1524-4733.2008.00472.x 18980633
8. Metastatic Non-small cell lung cancer: Costs associated with disease progression. Fox KM, Brooks JM, Kim J, Am J Manag Care 2008 14 9 565 71 18778171
9. The value of medical interventions for lung cancer in the elderly: Results from SEER-CMHSF. Woodward RM, Brown ML, Stewart ST, Cronin KA, Cutler DM, Cancer 2007 110 2511 8 10.1002/cncr.23058 17955504 (Pubitemid 350174938)
10. Differences in health care utilization at the end of life among patients with chronic obstructive pulmonary disease and patients with lung cancer. Au DH, Udris EM, Fihn SD, McDonell MB, Curtis R, Arch Intern Med 2006 166 326 311 10.1001/archinte.166.3.326 16476873 (Pubitemid 43244320)
11. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Kutikova L, Bowman L, Chang S, Long SR, Obasaju C, Crown WH, Lung Cancer 2005 50 143 54 10.1016/j.lungcan.2005.06.005 16112249 (Pubitemid 41427890)
12. Estimating medical costs from incomplete follow-up data. Lin DY, Feuer EJ, Etzioni R, Wax Y, Biometrics 1997 53 419 434 10.2307/2533947 9192444 (Pubitemid 27262208)
13. Bootstrap Methods: Another look at the jackknife. Efron B, The Annals of Statistics 1979 7 1 1 26 10.1214/aos/1176344552
14. The utility of Medicare claims for measuring cancer stage. Cooper GS, Yuan Z, Stange KC, Amini SB, Dennis LK, Rimm AA, Medical Care 1999 37 7 706 711 10.1097/00005650-199907000-00010 10424641